2013
SAT0267 Safety of Ustekinumab from the Placebo-Controlled Periods of Psoriatic Arthritis and Psoriasis Clinical Developmental Programs
McInnes I, Papp K, Puig L, Reich K, Ritchlin C, Strober B, Rahman P, Kavanaugh A, Mendelsohn A, Song M, Chan D, Shen Y, Li S, Gottlieb A. SAT0267 Safety of Ustekinumab from the Placebo-Controlled Periods of Psoriatic Arthritis and Psoriasis Clinical Developmental Programs. Annals Of The Rheumatic Diseases 2013, 72: a673. DOI: 10.1136/annrheumdis-2013-eular.1992.Peer-Reviewed Original ResearchGrant/research supportPsA populationOverall safety ratePsO/PsASafety event rateRates of AEsHigh rateActive PsA.Pt-yrRelevant comorbiditiesMedian durationPASI scorePsoriatic arthritisSkin involvementConcurrent therapyBSA involvementMedical historyFamily historySafety rateOverall AEEvent ratesPSAConfidence intervalsSimilar proportionsResearch support
2012
Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases
de Souza A, Ali‐Shaw T, Reddy S, Fiorentino D, Strober B. Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases. British Journal Of Dermatology 2012, 168: 210-212. PMID: 23278559, DOI: 10.1111/j.1365-2133.2012.11206.x.Peer-Reviewed Original ResearchConceptsUstekinumab treatmentHuman immunoglobulin G1κ monoclonal antibodyChronic inflammatory skin conditionInflammatory skin conditionT helper 1Common p40 subunitT cell differentiationIL-23Inflammatory arthritisPsoriatic arthritisTh17 pathwayFamily historyP40 subunitSkin conditionsCell activationArthritisPsoriasisMonoclonal antibodiesPatientsTreatmentReportUstekinumabTh1InterleukinAntibodies